Zenas BioPharma, Inc. (ZBIO) FY2026 Q2 P&L / Income Statement

Zenas BioPharma, Inc. (ZBIO) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. Consolidated revenue, costs and expenses.

Total revenue

1,000,000 US dollars

Total operating expenses

108,659,000 US dollars

Loss from operations

negative 107,659,000 US dollars

Total other income (expense), net

negative 3,683,000 US dollars

Loss before income taxes

negative 111,342,000 US dollars

Income tax provision (benefit)

114,000 US dollars

Net loss

negative 111,456,000 US dollars

Undisclosed sources

1,000,000 US dollars. The filing reports revenue as one line and discloses no sources of it.

Total operating expenses

108,659,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.